^
Association details:
| Biomarker: | IDH2 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E |
|---|---|
| Cancer: | Oligodendroglioma |
| Drug: | Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor) + Cotellic (cobimetinib) (MEK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
ADULT GLIOMA: OLIGODENDROGLIOMA (IDH-MUTANT, 1p19q CODELETED)….Recurrent or Progressive Disease WHO grade 2, KPS ≥60...Useful in Certain Circumstances...BRAF V600E activation mutation...BRAF/MEK inhibitors:…Vemurafenib/cobimetinib
